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Update on C-reactive protein as a risk marker in cardiovascular Moreover, according to current strategies, persistent ele-
disease. Atherosclerosis is characterized by a nonspecific local vation of hs-CRP levels after optimal treatment of unsta-
inflammatory process, which is accompanied by a systemic re- ble angina, measured at the time of hospital discharge,sponse. A number of prospective studies have convincingly
are predictive of recurrent events [6]. Thus, from the clini-demonstrated a strong and independent association between
cal point of view, hs-CRP testing represents a valuableeven slightly elevated concentrations of systemic markers of
inflammation, like C-reactive protein (CRP), and cardiovascu- additional diagnostic tool. Interestingly, subjects with
lar events in initially healthy subjects and in patients with unheralded acute MI showed normal hs-CRP levels in
manifest atherosclerosis. Increased concentrations of CRP
the majority of cases, compared with subjects with pre-were also associated with recurrent instability after discharge,
infarction angina pectoris [7]. This may serve as a clueand with early and late complications after percutaneous inter-
ventions, bypass operation, and in patients with end-stage renal that different pathophysiologies are involved in subjects
disease. Recent data have strengthened the role for CRP testing with an acute coronary syndrome.
in primary prevention, and potentially new indications like
glucose disorders have emerged. In addition, new experimental
data suggest that CRP may not only be a risk marker, but may NEW FINDINGS IN PRIMARY PREVENTION
be directly involved in the pathogenesis of atherothrombosis.
More recent data have strongly supported the addi-Testing the “inflammation hypothesis” now represents an im-
portant goal for clinical research of atherosclerosis. tional value of hs-CRP for cardiovascular risk assessment
in primary prevention. They also suggest that hs-CRP
is superior to other markers of inflammation for risk
evaluation [8]. Whereas current guidelines recommend
a lipid profile as the only blood test, compelling evidenceCRP RISK PREDICTION: WHAT IS
suggests considerable improvement of risk prediction byALREADY KNOWN
adding measurement of hs-CRP [9]. An initial report by
The role of elevated high-sensitivity (hs) C-reactive Ridker et al [10] demonstrated that the combination
protein (CRP) as a risk marker for cardiovascular dis- of elevated hs-CRP (2.11 mg/L) and elevated total
eases, including coronary heart disease [1], stroke [2], cholesterol (TC,234 mg/dL) is associated with a 5-fold
and peripheral arterial disease [3], is well established
increased risk for coronary events, compared with a 1.5-
through consistent results from a number of prospective
fold and 2.3-fold increase, respectively, if only one pa-studies. But CRP also conveys important prognostic in-
rameter was elevated. The combined assessment of theformation in the setting of the acute coronary syndrome.
most powerful predictor among lipoproteins, the TC/Subjects presenting with unstable angina or non ST-ele-
HDL cholesterol ratio, and hs-CRP further improvedvation myocardial infarction (MI) and increased levels
risk estimates. In quintile analyses, those in the topof hs-CRP are candidates for a variety of adverse events
quintile of both hs-CRP and the TC/HDL cholesterollike recurrent angina, ST-elevation MI, or coronary
ratio exhibited an 8.7-fold increased risk, compared withdeath. This holds true for short-term, in-hospital compli-
a 2.2-fold and a 4.2-fold increase in risk if the subjectcations, but also long-term over years, as has recently
belonged in the top quintile of TC/HDL cholesterol ra-been shown convincingly by data from the Fragmin dur-
tio, the top quintile of hs-CRP alone, and the bottoming Instability in Coronary Artery Disease (FRISC) trial
quintile of the respective variable [11].[4]. Even in the presence of results of troponin measure-
Data from the Air Force/Texas Coronary Atheroscle-ments, hs-CRP adds relevant prognostic information [5].
rosis Prevention Study (AFCAPS/TexCAPS) trial in pri-
mary prevention have shown that lovastatin effectively
reduced cardiovascular end points in those with LDL- 2003 by the International Society of Nephrology
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cholesterol levels 150 mg/dL, with or without elevated drive the acute-phase response, the attenuation of the
hs-CRP concentrations (1.65 mg/L). Interestingly, lova- association is plausible, and a model not including BMI
statin was equally effective in those with high CRP con- as a covariate might best express the full DM risk associ-
centrations, but with low LDL levels 150 mg/dL [12]. ated with markers of inflammation. An association of simi-
This finding clearly supports a central role of inflamma- lar magnitude was seen in elderly subjects (65 years)
tion in cardiovascular complications and underlines the participating in the Cardiovascular Health Study (CHS)
importance of hs-CRP measurement in these patients. during 3 to 4 years of follow up. In that study, other
Yet, before targeting statin use by hs-CRP measurements, markers of inflammation were not associated with DM.
this concept has to be tested formally in an adequately
sized, randomized, controlled clinical trial, which will be
CRP AND THE INSULINlaunched in the near future.
RESISTANCE SYNDROME
Several studies have investigated the association be-
NEW INDICATIONS FOR CRP TESTING: tween CRP and measures of insulin resistance. Although
GLUCOSE DISORDERS definitions differed slightly among them, CRP concentra-
It is now well documented that type-2 diabetes mellitus tions were consistently associated with the various com-
(DM), without presence of coronary heart disease (CHD), ponents of this syndrome. In the Insulin Resistance Ath-
is associated with a risk for coronary events similar to erosclerosis Study (IRAS), CRP was positively and
the risk in patients who have already suffered an acute significantly correlated with fasting glucose, fasting insu-
MI, but who are nondiabetic. Furthermore, risk factors lin, as well as with intact and split proinsulin. In 1653
are similar for both diseases, supporting the concept of individuals aged 55 to 74 years participating in a popula-
a “common soil” hypothesis [13]. Thus, it seems conceiv- tion-based survey in southern Germany, a standard oral
able to suggest that inflammation may also play a role glucose tolerance test (OGTT) was done in those without
in the pathogenesis of type-2 DM, and indeed, earlier history of manifest DM. Eighty randomly selected sub-
studies have found increased levels of markers of sys- jects with impaired glucose tolerance (IGT) were com-
temic inflammation in patients with manifest type-2 DM, pared with 80 nondiabetic controls and 152 patients with
and prognosis of diabetic patients has been linked to type-2 DM after matching for age and gender. Concen-
such markers of inflammation [14]. trations of CRP, serum amyloid A (SAA), and fibrinogen
were significantly elevated in subjects with IGT and type-2
DM compared with controls. No significant difference
CRP AND INCIDENT DIABETES
was seen between those with IGT and patients with type-2
Only recently, the first prospective study relating hs- DM. Thus, the full inflammatory risk may already be
CRP to incident type-2 DM was published. Using a present before manifestation of type-2 DM. A similar
nested case-control design within the ongoing Women’s elevation was seen for IL-6 and the soluble IL-6 receptor
Health Study (WHS), 188 women who developed DM known to potentiate IL-6 bioactivity. Differences in BMI
over four years were matched with 362 disease-free con- could not explain these findings.
trols. Unadjusted quartile analysis showed an extremely
strong association with an odds ratio (OR) of almost 16
CRP AS A PREDICTOR OF CLINICAL(Q4 vs. Q1), which was considerably attenuated to 4.4
OUTCOME IN END-STAGE RENAL DISEASE(95% CI, 1.5–12.0) after adjusting for BMI, but remained
essentially unchanged after further adjustments for other Patients with end-stage renal disease (ESRD) are at
risk factors, including fasting insulin levels. Results for si- high risk for cardiovascular complications. Recent stud-
multaneously assessed IL-6 levels became nonsignificant ies have accumulated compelling evidence for a role of
only after adjustment for other risk factors. CRP in improving risk prediction in this setting [15]
The association between CRP and risk of incident DM (Table 1).
was also analyzed in 2052 men aged 45 to 74 years in the
Monitoring of trends and determinants in cardiovascular
CRP: RISK MARKER OR RISK FACTOR?disease (MONICA) Augsburg cohort study after an av-
Increasing evidence suggests that CRP may be directlyerage of 7.2 years of follow up. In crude analysis using
involved in atherothrombogenesis that extends beyonda Cox proportional hazards model, an almost 3-fold in-
its previously accepted role as an inflammatory marker.creased risk was associated with CRP values in the top
CRP is present in the vessel wall, where it induces expres-quartile compared with the bottom quartile. Adjustment
sion of the adhesion molecules E-selectin, VCAM-1, andfor BMI reduced the observed association markedly and
ICAM-1 by endothelial cells, and serves as a chemo-it became nonsignificant. However, since adipocytes seem
to be the major source of pro-inflammatory cytokines that attractant for monocytes as mediated by induction of
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Table 1. Elevated CRP as a predictor of clinical outcome in ESRD patients
Author Year Study group FU mo Outcome parameter Outcome predictor
Bergstro¨m et al 1995 128 (HD) 48 All-cause mortality CRP
Owen et al 1998 1054 (HD) 6 All-cause mortality Alb, Cre, TLC, not CRP
Noh et al 1998 106 (PD) 24 All-cause mortality CRP, CVD, Hct
Ikizler et al 1999 73 (HD) 15 Hospitalization CRP, LBM
Zimmermann et al 1999 280 (HD) 24 All-cause and CV mortality CRP, age
Iseki et al 1999 163 (HD) 84 All-cause mortality CRP
Yeun et al 2000 91 (HD) 34 All-cause and CV mortality CRP, age
Abbreviations are: Alb, albumin; Cre, creatinine; TLC, total lymphocyte count; LBM, lean body mass; Hct, hematocrit; HD, hemodialysis; PD, peritoneal dialysis;
CV, cardiovascular; FU, follow-up. Adapted from Arici and Walls [25]. Reprinted with permission from Kidney International.
MCP-1. CRP opsonizes LDL and facilitates native LDL of CRP in atherogenesis. This might be of major impor-
tance for the advancement of our understanding of ath-entry into macrophages. CRP binds to plasma mem-
branes of damaged cells and activates complement via erosclerosis and may open new horizons to combat this
the classical pathway; an intact complement system far spreading disease.
seems to be crucial for maturation of atherosclerotic
Reprint requests to Wolfgang Koenig, M.D., FESC, FACC Professorlesions [17]. CRP is associated with endothelial cell dys- of Medicine/Cardiology, Department of Internal Medicine II–Cardiology,
function and progression of atherosclerosis, possibly by University of Ulm Medical Center, Robert-Koch Str. 8 D - 89081 Ulm,
Germany.decreasing nitric oxide synthesis [18]; it predicts en-
E-mail: wolfgang.koenig@medizin.uni-ulm.dehanced vasoreactivity of the culprit lesion in patients
with unstable angina. In line with these observations is
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